Patents by Inventor Andrew A. Dahl

Andrew A. Dahl has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20250143221
    Abstract: An over-center latch for a concave combine comprises a mount directly attached to a concave combine or an accessory for a concave combine, a base plate, a lever with a loop at one end that is configured to attach to a catch, and a center pin that allows the lever to rotate with respect to a handle. Either the handle or the lever can be pulled into a vertical position.
    Type: Application
    Filed: January 7, 2025
    Publication date: May 8, 2025
    Inventors: Andrew Dahl, Marion Calmer, Daniel Wallerstedt
  • Publication number: 20250143222
    Abstract: A concave system for a combine harvester, including a concave configured to be placed within the combine harvester around a rotor positioned within the combine harvester, a cover plate or MOG limiter; and an over-center latch assembly including a base plate, a handle, a lever, and a loop. Further, a kit including one or more concaves, cover plates and/or MOG limiters, one or more over-center latches, one or more linchpins, and one or more wire lock clevis pins.
    Type: Application
    Filed: January 7, 2025
    Publication date: May 8, 2025
    Inventors: Andrew Dahl, Marion Calmer, Daniel Wallerstedt
  • Publication number: 20250129130
    Abstract: Compounds capable of selectively modulating the TLR signaling pathway provide an improved treatment method for a broad variety of diseases in both animals and humans. The mechanisms of action in the treatment and/or prevention of coccidiosis and other conditions related to gut inflammation are via a direct effect on innate and adaptive immune pathways. The downstream results are improvements in performance parameters related to gut health (including altering gut microbes, conversion rates, and body weight gains among others. When administered to animals, the bioactives of the disclosed inventive compound mitigate the effects of coccidiosis via an enhanced immune response rather than a direct effect on parasites, such as the Eimeria parasite. The mechanisms of action of the disclosed inventive compound and method are via immune system priming rather than a direct effect on pathogens, thus there is no risk of treatment resistance being developed.
    Type: Application
    Filed: December 26, 2024
    Publication date: April 24, 2025
    Applicant: ZIVO BIOSCIENCE, INC.
    Inventors: Andrew A. Dahl, William P. Pfund, Amy E. Steffek
  • Publication number: 20250121012
    Abstract: A treatment compound and its use in the prevention and treatment diseases are disclosed. The compound comprises one or more materials selected from an algal biomass/supernatant (including both algae and bacteria), a bacterial biomass, and isolated and purified compound(s) as well as specific active sites or structures on those compounds. The bacteria are selected from the group consisting of Algoriphagus sp., Bosea sp., Brevundimonas sp., Desulfovibrio sp., Microbacterium sp., Sphingomonas sp., and Variovorax sp. The disclosed inventive compound and method of treatment find particular application in the treatment of disease in poultry, particularly in the prevention and treatment of coccidiosis.
    Type: Application
    Filed: December 19, 2024
    Publication date: April 17, 2025
    Applicant: Zivo Bioscience, Inc.
    Inventors: Amy E. Steffek, William P. Pfund, Andrew A. Dahl
  • Patent number: 12225855
    Abstract: An over-center latch for a concave combine comprises a mount directly attached to a concave combine or an accessory for a concave combine, a pentagonal base plate formed from steel, a lever with a loop at one end that is configured to attach to a catch plate, and a center pin that allows the lever to rotate with respect to a handle. Either the handle or the lever can be pulled into a vertical position.
    Type: Grant
    Filed: May 28, 2024
    Date of Patent: February 18, 2025
    Assignee: CALMER HOLDING COMPANY, LLC
    Inventors: Andrew Dahl, Marion Calmer, Daniel Wallerstedt
  • Publication number: 20240350623
    Abstract: A method and compound for altering the status of both innate and adaptive immune pathways in both animals and humans are disclosed. The status alteration results in the immune response being primed whereby an accelerated and more robust response is generated when the animal or human is challenged by pathogens that lead to a wide range of disease states. The disclosed method utilizes a compound derived from a lipopolysaccharide (LPS) of gram-negative bacteria. The compound itself is a natural product with no observed adverse environmental impact. By priming the immune pathways according to the disclosed inventive concept, the severity of various disease states can be reduced, can be resolved more quickly, or can be avoided entirely.
    Type: Application
    Filed: February 16, 2024
    Publication date: October 24, 2024
    Applicant: Zivo Bioscience, Inc.
    Inventors: Amy E. Steffek, Andrew A. Dahl, William P. Pfund
  • Publication number: 20240306551
    Abstract: A MOG limiting device, herein described as a MOG limiter, approximates a portion of the curvilinear length of a concave. The MOG limiting device can include a connection point near the middle of a concave, slightly offset from center. A bolt, washer and nut assembly protrudes downwardly from the underside of the concave. Two assemblies are positioned in the middle of each side of the concave. The assemblies cooperate with a mounting plate on the MOG limiters to form an upper concave connection and a lower concave connection in each half of the concave. In the cross frame, insert slots are positioned to receive a hinge point located at the end of each arced member making up the frame (rail supports). The hinge points are slidably inserted into the opening and then rotated upwardly to be positioned adjacent to and in conformity with the curvature of the underside of the concave with the connection assemblies holding the MOG limiter in place.
    Type: Application
    Filed: May 28, 2024
    Publication date: September 19, 2024
    Inventors: Andrew Dahl, Marion Calmer, Daniel Wallerstedt
  • Publication number: 20240172595
    Abstract: A MOG limiting device, herein described as a MOG limiter, approximates a portion of the curvilinear length of a concave. The MOG limiting device can include a connection point near the middle of a concave, slightly offset from center. A bolt, washer and nut assembly protrudes downwardly from the underside of the concave. Two assemblies are positioned in the middle of each side of the concave. The assemblies cooperate with a mounting plate on the MOG limiters to form an upper concave connection and a lower concave connection in each half of the concave. In the cross frame, insert slots are positioned to receive a hinge point located at the end of each arced member making up the frame (rail supports). The hinge points are slidably inserted into the opening and then rotated upwardly to be positioned adjacent to and in conformity with the curvature of the underside of the concave with the connection assemblies holding the MOG limiter in place.
    Type: Application
    Filed: November 28, 2023
    Publication date: May 30, 2024
    Inventors: Andrew Dahl, Marion Calmer, Daniel Wallerstedt
  • Patent number: 11806375
    Abstract: An algal biomass and supernatant derived from at least one species of algae exhibits the ability to maintain general health in humans and non-human animals and promote a healthy immune system in them. Food, feed and nutritional supplements comprising an algal biomass or supernatant derived from at least one species of algae are described. Methods of maintaining general health or promoting a healthy immune system in humans and non-human animals comprises administering to the animal in need thereof an algal biomass or supernatant derived from at least one species of algae, or an extract, derivative or homeopathic compound derived from the algae species, biomass or supernatant, or a composition thereof.
    Type: Grant
    Filed: February 15, 2017
    Date of Patent: November 7, 2023
    Assignee: Zivo Bioscience, Inc.
    Inventors: Andrew A. Dahl, Amy E. Steffek
  • Publication number: 20230338414
    Abstract: An effective treatment mechanism in controlling a variety of diseases by modulating the inflammatory response often associated with disease is disclosed. The disclosed inventive concept is based on the modulation of TLR4 by use of a member of the Variovorax group or the Rhodobacter group. Specifically, the Gram-negative bacterium Variovorax paradoxus or the Gram-negative bacterium Rhodobacter sphaeroides is used according to the disclosed inventive concept in the treatment of disease by reducing or inhibiting inflammatory responses.
    Type: Application
    Filed: April 26, 2023
    Publication date: October 26, 2023
    Applicant: ZIVO Bioscience, Inc.
    Inventors: Andrew A. Dahl, William P. Pfund, Amy E. Steffek
  • Publication number: 20230218681
    Abstract: An improved agent and treatment method for a broad variety of diseases in both animals and humans is disclosed. The agent is an inventive composition comprising a bacterial-based culture. Particularly, the inventive composition disclosed herein is an active molecule produced by a Gram-negative bacterial strain that is a member of the genus Brevundimonas. Consumption of the inventive composition by way of liquid or dry feed produces a broad range of health benefits and has proven effective in the prevention and treatment of disease. The bacterium of the disclosed composition selectively modulates Toll-like receptors (TLRs) for the prevention and treatment of disease such as coccidiosis. Specific actions include but are not limited to improvement of gut health, acceleration or enhancement of immune response using a natural immune modulator, and the promotion of animal growth.
    Type: Application
    Filed: December 7, 2022
    Publication date: July 13, 2023
    Applicant: Zivo Bioscience, Inc.
    Inventors: Amy E. Steffek, William P. Pfund, Andrew A. Dahl
  • Publication number: 20220240542
    Abstract: A method and compound for promoting growth and priming the immune system in both animals and humans are disclosed. The disclosed method utilizes a compound derived from one or more of a lipopolysaccharide, Lipid A, and fractions, derivatives, and cellular components thereof of gram-negative bacteria. The compound is combined with conventional feed, such as corn-soy feed, for administration to animals, such as poultry. Human application is possible, as well. Kinomic analysis of tissues collected from sacrificed birds fed the dietary mixture of the inventive compound and conventional feed suggests that the biomass causes an alteration of signaling in multiple growth-related pathways. These pathways include, but are not limited to, those associated with the vascular endothelial growth factor (VEGF), the mitogen-activated protein kinase (MAPK or MAP kinase), Ak strain transforming (Akt), and the neurotrophic tropomyosin-related kinase (NTRK).
    Type: Application
    Filed: January 28, 2022
    Publication date: August 4, 2022
    Applicant: ZIVO Bioscience, Inc.
    Inventors: William P. Pfund, Amy E. Steffek, Andrew A. Dahl
  • Publication number: 20220233608
    Abstract: A method and compound for promoting growth in both animals and humans are disclosed. The disclosed method utilizes a compound derived from a lipopolysaccharide (LPS) of gram-negative bacteria. The compound itself is a natural product with no observed adverse environmental impact. The compound is combined with conventional feed, such as a corn-soy feed, for administration to animals, such as poultry. Human application is possible, as well. The combination of the disclosed inventive compound and conventional feed works through multiple growth-related pathways within, for example, in healthy birds to enhance growth performance while also priming the immune system to expedite response to a disease challenge should one arise. Data indicate that the dietary mixture of the inventive compound in conventional feed suggests that the biomass alters the signaling of multiple growth-related pathways.
    Type: Application
    Filed: August 24, 2021
    Publication date: July 28, 2022
    Applicant: ZIVO Bioscience, Inc.
    Inventors: Amy E. Steffek, Andrew A. Dahl, William P. Pfund
  • Publication number: 20220226398
    Abstract: A treatment compound and its use in the prevention and treatment diseases are disclosed. The compound comprises one or more materials selected from an algal biomass/supernatant (including both algae and bacteria), a bacterial biomass, and isolated and purified compound(s) as well as specific active sites or structures on those compounds. The bacteria are selected from the group consisting of Algoriphagus sp., Bosea sp., Brevundimonas sp., Desulfovibrio sp., Microbacterium sp., Sphingomonas sp., and Variovorax sp. The disclosed inventive compound and method of treatment find particular application in the treatment of disease in poultry, particularly in the prevention and treatment of coccidiosis.
    Type: Application
    Filed: January 14, 2022
    Publication date: July 21, 2022
    Applicant: ZIVO Bioscience, Inc.
    Inventors: Amy E. Steffek, William P. Pfund, Andrew A. Dahl
  • Publication number: 20220226394
    Abstract: A treatment compound and its use in the prevention and treatment diseases are disclosed. The compound comprises one or more materials selected from an algal biomass/supernatant (including both algae and bacteria), a bacterial biomass, and isolated and purified compound(s) as well as specific active sites or structures on those compounds. The treatment compound and the use of such a compound such as that derived from a bacterium that appears to selectively alter one or more TLR pathways in the prevention and treatment of disease in both animals and humans. The bacteria are selected from the group consisting of Algoriphagus sp., Bosea sp., Brevundimonas sp., Desulfovibrio sp., Microbacterium sp., Sphingomonas sp., and Variovorax sp. The disclosed inventive compound and method of treatment find particular application in the treatment of disease in poultry, particularly in the prevention and treatment of coccidiosis.
    Type: Application
    Filed: January 14, 2022
    Publication date: July 21, 2022
    Applicant: ZIVO Bioscience, Inc.
    Inventors: Amy E. Steffek, William P. Pfund, Andrew A. Dahl
  • Publication number: 20220125859
    Abstract: An improved agent and treatment method for a broad variety of diseases in both animals and humans are disclosed. The agent is an inventive treatment compound comprising a bacterial-based culture. The inventive treatment compound has a positive impact on the gut health of boilers from the earliest stage onward. These benefits are realized through several mechanisms, including improved gut morphology under disease stress. Healthier gut morphology and improved gut integrity result in improved nutrient uptake and growth benefits, both based on consumption of the disclosed inventive treatment compound. The downstream results are improvements in performance parameters related to gut health including altering gut microbes, feed conversion rates, and body weight gains among others. Use of the disclosed treatment compound has the further benefit of avoiding contamination during animal processing because of the reduction in the volume of pathogenic bacteria in the gut.
    Type: Application
    Filed: September 2, 2021
    Publication date: April 28, 2022
    Applicant: ZIVO Bioscience, Inc.
    Inventors: Amy E. Steffek, William P. Pfund, Andrew A. Dahl
  • Publication number: 20220072074
    Abstract: An algal biomass used as a natural ingredient in poultry feed reverses the detrimental effects of coccidiosis and necrotic enteritis in poultry. Algal biomass augmented poultry feed was shown to improve feed conversion rates, reduce mortality rates, and reduce intestinal lesion scores. In various embodiments, the algal biomass comprises at least one species of Klebsormidium. In various aspects, the algal biomass may be obtaining by continuously cultivating at least one species of Klebsormidium in raceway ponds, separating the plant material and spray drying to obtain the algal biomass.
    Type: Application
    Filed: December 19, 2019
    Publication date: March 10, 2022
    Applicant: Zivo Bioscience, Inc.
    Inventors: Andrew A. Dahl, Amy E. Steffek, William P. Pfund
  • Publication number: 20220062403
    Abstract: An effective treatment method for a broad variety of diseases in both animals and humans is disclosed. The method includes combining one or more vaccines with a treatment compound to enhance vaccine efficacy. The disclosed treatment compound does not act directly on the pathogen, and thus the organisms cannot readily develop resistance to the treatment. When a compound such as, but not limited to, the disclosed compound is used in conjunction with one or more vaccines, a synergistic effect is realized. The suggested compound is derived from a lipopolysaccharide (LPS) of gram negative bacteria. The treatment compound is combined with one or more appropriate vaccines and is administered early in the life of an animal to achieve a synergistic effect compared with the use of the treatment compound or the vaccine alone.
    Type: Application
    Filed: July 2, 2021
    Publication date: March 3, 2022
    Applicant: ZIVO Bioscience, Inc.
    Inventors: Andrew A. Dahl, William P. Pfund, Amy E. Steffek
  • Patent number: D1058613
    Type: Grant
    Filed: November 29, 2022
    Date of Patent: January 21, 2025
    Assignee: CALMER HOLDING COMPANY, LLC
    Inventors: Andrew Dahl, Marion Calmer, Daniel Wallerstedt
  • Patent number: D1066427
    Type: Grant
    Filed: February 29, 2024
    Date of Patent: March 11, 2025
    Assignee: CALMER HOLDING COMPANY, LLC
    Inventors: Gene Colburn, Dan Akers, Marion Calmer, Andrew Dahl, Jay Dahl, Joe Edmonson, Daniel Wallerstedt